Videos Library

Event Videos

MedTech & Diagnostics Value & Access Developing global evidence & capabilities to demonstrate value and achieve market access in key local markets

Online Conference - 2 half days (8am NYC, 2pm Paris) - March 30-31, 2021

How value-based approach is transforming the MedTech industry

Related topics: MedTech, Market Access & HEOR
Availability: FREE
  • Integrating market access, medical affairs and deep clinical understanding
  • Building a strategy with KOL engagement and collaboration with scientific societies - a case study explaining the process and decision-making algorithms
  • Clinical guidelines, the reimbursement system and medical standards and protocols as a key focus of the strategy

Julya Zuenkova

Business Development Director
Xstrahl Group


From value-based healthcare to network value

Related topics: MedTech, Market Access & HEOR
Availability: FREE

COVID-19 significantly impacted how providers reach out to patients. Besides, there has been a series of changes in the reimbursement and funding of medical technologies and procedures. These aspects created opportunities to address new market needs and leverage data and learning to deliver more value to a growing network of payers, providers, and patients. Welcome to the new era of Network Value.


Ernesto M. Nogueira

CEO and Founder


Creating Product Value To Capture Market Opportunities in Post-COVID era – A multi-disciplinary roadmap for success

Related topics: MedTech, Market Access & HEOR
Availability: FREE
  • Key decisions of today that brings you into the world of opportunities tomorrow
  • Setting out Product Claims with recognizable aspirational value.
  • Understanding pricing & reimbursement landscape and payers needs
  • Designing adequate evidence to demonstrate this value for regulatory and reimbursement purposes.
  • Informed choices for stronger claims and data generation with the full circle of multi-disciplinary insights  
  • Defining key success factors to capture new market access opportunities

Claus Schaffrath

Managing Director, MD squared

Katarzyna Kolasa

Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University


Successful evidence development for global launches

Related topics: MedTech, Market Access & HEOR
Availability: FREE

In today's demanding world of national requirements, how can companies develop the right evidence portfolio to succeed? How can they integrate evidence for payers with their regulatory studies?  This in depth review will discuss core principles in evidence development for diagnostics and therapeutic medical devices, and how these concepts can align with the requirements of the major global markets -- the UK, France, Germany, Japan and the USA. Learn about the evolving landscape of evidence demands in:

  • The UK, with NICE's development of new pathways for innovative devices
  • France's Forfeit Innovation and evidence demands
  • Germany's NUB evidence review requirements for high risk devices
  • Japan's emerging new pathways for breakthrough innovations
  • The US Medicare programs special coverage of FDA designated Breakthrough Devices

Stephen Hull

Principal and Founder
Hull Associates